High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party
- Author(s)
- Ramamurthy, A; Connolly, EA; Mar, J; Lewin, J; Bhadri, VA; Phillips, MB; Winstanley, M; Orme, LM; Grimison, P; Connor, J; Lazarakis, S; Hong, AM; Omer, N; Cayrol, J;
- Journal Title
- Cancer Treatment Reviews
- Publication Type
- Review
- Abstract
- INTRODUCTION: Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities. METHODS: A systematic review was conducted, using the population, intervention, comparison outcome (PICO) model, to evaluate whether utilization of HDT/ASCT impacts the outcome of patients with ES and RMS compared to standard chemotherapy alone, as part of first line treatment or in the relapse setting. Medline, Embase and Cochrane Central were queried for publications from 1990 to October 2022 that evaluated event-free survival (EFS), overall survival (OS), and toxicities. Each study was screened by two independent reviewers for suitability. A qualitative synthesis of the results was performed. RESULTS: Of 1,172 unique studies screened, 41 studies were eligible for inclusion with 29 studies considering ES, 10 studies considering RMS and 2 studies considering both. In ES patients with high-risk localised disease who received HDT/ASCT after VIDE chemotherapy, consolidation with melphalan-based HDT/ASCT as first line therapy conveyed an EFS and OS benefit over standard chemotherapy consolidation. Efficacy of HDT/ASCT using a VDC/IE backbone, which is now standard care, has not been established. Survival benefits are not confirmed for ES patients with metastatic disease at initial diagnosis. For relapsed/refractory ES, four retrospective studies report improvement in outcomes with HDT/ASCT with the greatest evidence in patients who demonstrate a treatment response before HDT, and in patients under the age of 14. In RMS, there is no proven survival benefit of HDT/ASCT in primary localised, metastatic or relapsed disease. CONCLUSION: Prospective randomised trials are required to determine the utility of HDT/ASCT in ES and RMS. Selected patients with relapsed ES could be considered for HDT/ASCT.
- Publisher
- Elsevier
- Keywords
- Autologous stem cell transplant; Ewing Sarcoma; Guidelines; High dose chemotherapy; Paediatric oncology; Rhabdomyosarcoma; Sarcoma
- Department(s)
- AYA Cancer Service
- Publisher's Version
- https://doi.org/10.1016/j.ctrv.2024.102694
- Open Access at Publisher's Site
https://doi.org/10.1016/j.ctrv.2024.102694- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-26 02:32:36
Last Modified: 2024-03-26 02:56:13